

#7

0590
2/4

OIKE

RAW SEQUENCE LISTING

DATE: 02/13/2002

PATENT APPLICATION: US/09/765,614B

TIME: 12:28:40

Input Set : A:\PTO.txt

Output Set: N:\CRF3\02132002\I765614B.raw

6 <110> APPLICANT: Nycomed Imaging AS
 8 <120> TITLE OF INVENTION: Improvements in or relating to
 9 diagnostic/therapeutic
 10 agents
 12 <130> FILE REFERENCE: REF/Klaveness/054
 C--> 14 <140> CURRENT APPLICATION NUMBER: US/09/765,614B
 C--> 15 <141> CURRENT FILING DATE: 2001-07-10
 17 <160> NUMBER OF SEQ ID NOS: 31
 18 <170> SOFTWARE: PatentIn Ver. 2.1
 20 <210> SEQ ID NO: 1
 21 <211> LENGTH: 4
 22 <212> TYPE: PRT
 23 <213> ORGANISM: Artificial Sequence
 25 <220> FEATURE:
 26 <223> OTHER INFORMATION: Description of Artificial
 27 Sequence:RGDC-Mal-PEG3400-DSPE
 29 <400> SEQUENCE: 1
 30 Arg Gly Asp Cys
 32 1
 35 <210> SEQ ID NO: 2
 36 <211> LENGTH: 25
 37 <212> TYPE: PRT
 38 <213> ORGANISM: Artificial Sequence
 40 <220> FEATURE:
 41 <223> OTHER INFORMATION: Description of Artificial
 42 Sequence:Peptide
 43 comprising
 44 phosphatidylserine-binding and
 W--> 45 heparin-binding sections
 47 <400> SEQUENCE: 2
 48 Phe Asn Phe Arg Leu Lys Ala Gly Gln Lys Ile Arg Phe Gly Ala Ala
 50 1 5 10 15
 52 Ala Trp Glu Pro Pro Arg Ala Arg Ile
 53 20 25
 57 <210> SEQ ID NO: 3
 58 <211> LENGTH: 8
 59 <212> TYPE: PRT
 60 <213> ORGANISM: Artificial Sequence
 62 <220> FEATURE:
 63 <223> OTHER INFORMATION: Description of Artificial
 64 Sequence:Heparin-binding
 65 peptide
 67 <400> SEQUENCE: 3

ENTERED

RAW SEQUENCE LISTING

DATE: 02/13/2002

PATENT APPLICATION: US/09/765,614B

TIME: 12:28:40

Input Set : A:\PTO.txt

Output Set: N:\CRF3\02132002\I765614B.raw

```

68 Trp Glu Pro Pro Arg Ala Arg Ile
69   1           5
73 <210> SEQ ID NO: 4
74 <211> LENGTH: 6
75 <212> TYPE: PRT
76 <213> ORGANISM: Artificial Sequence
78 <220> FEATURE:
79 <223> OTHER INFORMATION: Description of Artificial
80   Sequence:Linker sequence
82 <220> FEATURE:
83 <221> NAME/KEY: MOD_RES
84 <222> LOCATION: (1)
85 <223> OTHER INFORMATION: MTX-phenylalanine
87 <400> SEQUENCE: 4
88 Phe Lys Leu Arg Leu Cys
89   1           5
93 <210> SEQ ID NO: 5
94 <211> LENGTH: 4
95 <212> TYPE: PRT
96 <213> ORGANISM: Artificial Sequence
98 <220> FEATURE:
99 <223> OTHER INFORMATION: Description of Artificial
100   Sequence:Heparin
101   sulphate binding peptide
103 <400> SEQUENCE: 5
104 Lys Arg Lys Arg
105   1
109 <210> SEQ ID NO: 6
110 <211> LENGTH: 8
111 <212> TYPE: PRT
112 <213> ORGANISM: Artificial Sequence
114 <220> FEATURE:
115 <223> OTHER INFORMATION: Description of Artificial
116   Sequence:Fibronectin
117   peptide
119 <400> SEQUENCE: 6
120 Trp Gln Pro Pro Arg Ala Arg Ile
121   1           5
125 <210> SEQ ID NO: 7
126 <211> LENGTH: 13
127 <212> TYPE: PRT
128 <213> ORGANISM: Artificial Sequence
130 <220> FEATURE:
131 <223> OTHER INFORMATION: Description of Artificial
132   Sequence:Lipopeptide
133   consisting of a heparin
134   sulphate binding peptide
W--> 135   and a fibronectin peptide
137 <220> FEATURE:

```

RAW SEQUENCE LISTING

DATE: 02/13/2002

PATENT APPLICATION: US/09/765,614B

TIME: 12:28:40

Input Set : A:\PTO.txt

Output Set: N:\CRF3\02132002\I765614B.raw

```

138 <221> NAME/KEY: MOD_RES
139 <222> LOCATION: (1)
140 <223> OTHER INFORMATION: Dipalmitoyl-lysine
142 <400> SEQUENCE: 7
143 Lys Lys Arg Lys Arg Trp Gln Pro Pro Arg Ala Arg Ile
144 1          5          10
148 <210> SEQ ID NO: 8
149 <211> LENGTH: 24
150 <212> TYPE: PRT
151 <213> ORGANISM: Artificial Sequence
153 <220> FEATURE:
154 <223> OTHER INFORMATION: Description of Artificial
155     Sequence:Fibronectin
156     peptide sequence
158 <400> SEQUENCE: 8
159 Phe Asn Phe Arg Leu Lys Ala Gly Gln Lys Ile Arg Phe Gly Gly Gly
161 1          5          10          15
163 Gly Trp Gln Pro Pro Arg Ala Ile
164     20
168 <210> SEQ ID NO: 9
169 <211> LENGTH: 6
170 <212> TYPE: PRT
171 <213> ORGANISM: Artificial Sequence
173 <220> FEATURE:
174 <223> OTHER INFORMATION: Description of Artificial
175     Sequence:Biotinylated
176     endothelin-1 peptide
178 <220> FEATURE:
179 <221> NAME/KEY: MOD_RES
180 <222> LOCATION: (1)
181 <223> OTHER INFORMATION: Biotin-D-Trp
183 <400> SEQUENCE: 9
184 Trp Leu Asp Ile Ile Trp
185 1          5
189 <210> SEQ ID NO: 10
190 <211> LENGTH: 10
191 <212> TYPE: PRT
192 <213> ORGANISM: Artificial Sequence
194 <220> FEATURE:
195 <223> OTHER INFORMATION: Description of Artificial
196     Sequence:Biotinylated
197     fibrin-anti-polymerant peptide
199 <220> FEATURE:
200 <221> NAME/KEY: MOD_RES
201 <222> LOCATION: (1)
202 <223> OTHER INFORMATION: Biotinylated-Gly
204 <220> FEATURE:
205 <221> NAME/KEY: MOD_RES
206 <222> LOCATION: (10)

```

RAW SEQUENCE LISTING

DATE: 02/13/2002

PATENT APPLICATION: US/09/765,614B

TIME: 12:28:40

Input Set : A:\PTO.txt

Output Set: N:\CRF3\02132002\I765614B.raw

```

207 <223> OTHER INFORMATION: AMIDATION
209 <400> SEQUENCE: 10
210 Gly Pro Arg Pro Pro Glu Arg His Gln Ser
212 1          5          10
216 <210> SEQ ID NO: 11
217 <211> LENGTH: 5
218 <212> TYPE: PRT
219 <213> ORGANISM: Artificial Sequence
221 <220> FEATURE:
222 <223> OTHER INFORMATION: Description of Artificial
223     Sequence:Lipopeptide
224     containing RGD sequence and
225     fluorescein reporter
W--> 226     group
228 <220> FEATURE:
229 <221> NAME/KEY: MOD_RES
230 <222> LOCATION: (1)
231 <223> OTHER INFORMATION: Dipalmitoyl-Lys
233 <220> FEATURE:
234 <221> NAME/KEY: MOD_RES
235 <222> LOCATION: (4)
236 <223> OTHER INFORMATION: Acetyl-RGD-K-fluorescein side
237     chain
239 <400> SEQUENCE: 11
240 Lys Lys Lys Lys Gly
241 1          5
245 <210> SEQ ID NO: 12
246 <211> LENGTH: 18
247 <212> TYPE: PRT
248 <213> ORGANISM: Artificial Sequence
250 <220> FEATURE:
251 <223> OTHER INFORMATION: Description of Artificial
252     Sequence:Endothelial
253     cell binding lipopeptide
255 <220> FEATURE:
256 <221> NAME/KEY: MOD_RES
257 <222> LOCATION: (1)
258 <223> OTHER INFORMATION: 2-n-hexadecylstearyl-Lys
260 <220> FEATURE:
261 <221> NAME/KEY: MOD_RES
262 <222> LOCATION: (18)
263 <223> OTHER INFORMATION: AMIDATION
265 <400> SEQUENCE: 12
266 Lys Leu Ala Leu Lys Leu Ala Leu Lys Ala Leu Lys Ala Ala Leu Lys
268 1          5          10          15
270 Leu Ala
275 <210> SEQ ID NO: 13
276 <211> LENGTH: 4
277 <212> TYPE: PRT

```

RAW SEQUENCE LISTING

DATE: 02/13/2002

PATENT APPLICATION: US/09/765,614B

TIME: 12:28:40

Input Set : A:\PTO.txt

Output Set: N:\CRF3\02132002\I765614B.raw

```

278 <213> ORGANISM: Artificial Sequence
280 <220> FEATURE:
281 <223> OTHER INFORMATION: Description of Artificial
282     Sequence:Lipopeptide
283     functionalised with captopril
285 <220> FEATURE:
286 <221> NAME/KEY: MOD_RES
287 <222> LOCATION: (1)
288 <223> OTHER INFORMATION: Dipalmitoyl-Lys
290 <220> FEATURE:
291 <221> NAME/KEY: MOD_RES
292 <222> LOCATION: (4)
293 <223> OTHER INFORMATION: Amide linked via side chain to
294     captopril
296 <220> FEATURE:
297 <221> NAME/KEY: MOD_RES
298 <222> LOCATION: (4)
299 <223> OTHER INFORMATION: AMIDATION
301 <400> SEQUENCE: 13
302 Lys Lys Lys Lys
303 1
307 <210> SEQ ID NO: 14
308 <211> LENGTH: 13
309 <212> TYPE: PRT
310 <213> ORGANISM: Artificial Sequence
312 <220> FEATURE:
313 <223> OTHER INFORMATION: Description of Artificial
314     Sequence:Lipopeptide
315     with an affinity for
316     endothelial cells
318 <220> FEATURE:
319 <221> NAME/KEY: MOD_RES
320 <222> LOCATION: (1)
321 <223> OTHER INFORMATION: Dipalmitoyl-Lys
323 <220> FEATURE:
324 <221> NAME/KEY: MOD_RES
325 <222> LOCATION: (4)
326 <223> OTHER INFORMATION: Acp
328 <220> FEATURE:
329 <221> NAME/KEY: MOD_RES
330 <222> LOCATION: (13)
331 <223> OTHER INFORMATION: AMIDATION
333 <400> SEQUENCE: 14
W--> 334 Lys Lys Lys Xaa Ile Arg Arg Val Ala Arg Pro Pro Leu
336 1          5          10
340 <210> SEQ ID NO: 15
341 <211> LENGTH: 14
342 <212> TYPE: PRT
343 <213> ORGANISM: Artificial Sequence

```

VERIFICATION SUMMARY

DATE: 02/13/2002

PATENT APPLICATION: US/09/765,614B

TIME: 12:28:41

Input Set : A:\PTO.txt

Output Set: N:\CRF3\02132002\I765614B.raw

L:14 M:270 C: Current Application Number differs, Replaced Current Application Number
L:15 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:45 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:135 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:226 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:334 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14
L:350 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:385 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:386 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:486 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20